NCT00785759

Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers

An Open-label Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 78 (actual)
• Sponsor: GE Healthcare · Industry
• Sex: All
• Age: 25 Years
• Healthy volunteers: Accepted

Summary

Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects with Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers.

Conditions

• Alzheimer's Disease
• Amnestic Mild Cognitive Impairment

Interventions

Type	Name	Description
DRUG	AH110690 (18F) Injection	All subjects will receive an I.V. dose of \[18F\]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of \[18F\]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-03-01
• Completion: 2009-12-01
• First posted: 2008-11-05
• Last updated: 2009-12-07

Locations

1 site across 1 country: Norway